Abstract
New drugs are desperately needed to combat XDR-TB as effective treatment involves at least four drugs to which the patient is sensitive or has never received in the past. Most Indian patients have received almost all second line drugs and have amplified resistance to most of the available drugs. Thioridazine has proven anti tuberculous effects in vitro and in vivo mouse models and we used this drug as salvage therapy in 4 Indian patients with XDR (near total drug resistance) with advanced disease. We found this drug to be well tolerated, even in this malnourished and ill patient population. It also resulted in clinical improvement in 3 of the 4 patients. Larger studies are being planned with this drug being added on to standardized or individualized XDR-TB regimens at an earlier stage. Because thioridazine has been used successfully for therapy of XDR-TB when in combination with antibiotics to which the patients were nonresponsive, the suggestion has been made that Thioridazine is eligible for patent as “New Use”.
Keywords: Thioridazine, salvage drug, XDR-TB, QT-interval, TB Strains, sputum conversion, central inflammatory response, antituberculous effects, drug resistant tuberculosis, thioridazine therapy
Recent Patents on Anti-Infective Drug Discovery
Title: Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB
Volume: 6 Issue: 2
Author(s): Zarir F. Udwadia, Tiyas Sen and Lancelot M. Pinto
Affiliation:
Keywords: Thioridazine, salvage drug, XDR-TB, QT-interval, TB Strains, sputum conversion, central inflammatory response, antituberculous effects, drug resistant tuberculosis, thioridazine therapy
Abstract: New drugs are desperately needed to combat XDR-TB as effective treatment involves at least four drugs to which the patient is sensitive or has never received in the past. Most Indian patients have received almost all second line drugs and have amplified resistance to most of the available drugs. Thioridazine has proven anti tuberculous effects in vitro and in vivo mouse models and we used this drug as salvage therapy in 4 Indian patients with XDR (near total drug resistance) with advanced disease. We found this drug to be well tolerated, even in this malnourished and ill patient population. It also resulted in clinical improvement in 3 of the 4 patients. Larger studies are being planned with this drug being added on to standardized or individualized XDR-TB regimens at an earlier stage. Because thioridazine has been used successfully for therapy of XDR-TB when in combination with antibiotics to which the patients were nonresponsive, the suggestion has been made that Thioridazine is eligible for patent as “New Use”.
Export Options
About this article
Cite this article as:
F. Udwadia Zarir, Sen Tiyas and M. Pinto Lancelot, Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB, Recent Patents on Anti-Infective Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489111796064614
DOI https://dx.doi.org/10.2174/157489111796064614 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Atrial Fibrillation in Autoimmune Rheumatic Diseases: from Pathogenesis to Treatment
Reviews on Recent Clinical Trials Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism A Review of Feature Extraction from ECG Signals and Classification/ Detection for Ventricular Arrhythmias
Recent Advances in Computer Science and Communications Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury
Endocrine, Metabolic & Immune Disorders - Drug Targets Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry Defining the Pharmaceutical System to Support Proactive Drug Safety
Current Drug Safety Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Bio-Active Chemical Constituents from the Genus Streptocaulon
Mini-Reviews in Organic Chemistry In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology
Combinatorial Chemistry & High Throughput Screening Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Current Neuropharmacology